Prime Therapeutics plans to examine the total healthcare costs for Boehringer Ingelheim's SGLT2 drug Jardiance versus the competition.
Novartis investors were disappointed when CEO Joe Jimenez said that a decision about eye unit Alcon would be delayed.
Novartis is only in the very early days of its Kymriah rollout in the U.S., but company executives aren't only focusing on the States.
Despite lots of value-based talk, a new PwC survey finds the new payer contracting approach has yet to take off in a major way.
Novartis' Entresto to treat heart failure had a tough launch at $4,600 a year, but the product is starting to turn around.
Outcome Health says it's zeroing in on healthcare results, just as pharma embraces a similar evidence-based philosophy.
On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim.
Facing stepped-up competition for its critical MS franchise, Biogen CEO Michel Vounatsos says his company's ready to try some "innovative" payer deals.
Smart pharma CEOs are getting ahead of the drug pricing argument. Rather than getting in the trenches to defend their price tags, they’re flanking the fight by talking up value-based payer deals.
Add Merck to the list of companies participating in pay-for-performance deals. Facing stepped-up competition in diabetes, the pharma signed a value-based contract with leading insurer Aetna for its Januvia and Janumet.